Author:
Ganetsky Michael,Babu Kavita M.,Salhanick Steven D.,Brown Robert S.,Boyer Edward W.
Publisher
Springer Science and Business Media LLC
Subject
Health, Toxicology and Mutagenesis,Toxicology
Reference40 articles.
1. Wann LS, Curtis AB, Ellenbogen KA et al (2011) 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 57(11):1330–1337
2. Melnikova I (2009) The anticoagulants market. Nat Rev Drug Discov 8(5):353–354
3. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W (2002) Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 45(9):1757–1766
4. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N (2007) In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 98(1):155–162
5. Di Nisio M, Middeldorp S, Buller HR (2005) Direct thrombin inhibitors. N Engl J Med 353(10):1028–1040
Cited by
122 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献